Teemu Sorsa , Eva M. del Amo , Amir Sadeghi , Jonna Laitinen , Iuliia Pilipenko , Arto Urtti , Astrid Subrizi
{"title":"玻璃体内小分子药物溶出与释放研究的新型体外模型及其长效制剂","authors":"Teemu Sorsa , Eva M. del Amo , Amir Sadeghi , Jonna Laitinen , Iuliia Pilipenko , Arto Urtti , Astrid Subrizi","doi":"10.1016/j.jconrel.2025.113823","DOIUrl":null,"url":null,"abstract":"<div><div>Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality <em>in vivo</em> experiments that require a large number of animals. This development can be expedited by improving <em>in vitro</em> testing and utilizing <em>in vitro</em> – <em>in vivo</em> correlation. We propose an <em>in vitro</em> approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"383 ","pages":"Article 113823"},"PeriodicalIF":10.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations\",\"authors\":\"Teemu Sorsa , Eva M. del Amo , Amir Sadeghi , Jonna Laitinen , Iuliia Pilipenko , Arto Urtti , Astrid Subrizi\",\"doi\":\"10.1016/j.jconrel.2025.113823\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality <em>in vivo</em> experiments that require a large number of animals. This development can be expedited by improving <em>in vitro</em> testing and utilizing <em>in vitro</em> – <em>in vivo</em> correlation. We propose an <em>in vitro</em> approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.</div></div>\",\"PeriodicalId\":15450,\"journal\":{\"name\":\"Journal of Controlled Release\",\"volume\":\"383 \",\"pages\":\"Article 113823\"},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Controlled Release\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168365925004432\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925004432","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations
Intravitreal drug delivery is essential for multiple ocular diseases. Development of intravitreal formulations requires high-quality in vivo experiments that require a large number of animals. This development can be expedited by improving in vitro testing and utilizing in vitro – in vivo correlation. We propose an in vitro approach using vitreous in a dialysis membrane to conduct these studies. The model was developed for small molecules and evaluated with drugs in solution (13 drugs in one cassette and 4 in another), and a drug suspension. For solutions, 6 out of 8 drug compounds were within 2.5-fold difference to their experimental vitreal clearances. Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.